Topic

Mike Hennessy Jr. is the President and CEO of 

Articles

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Paradigm Shift

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.

Of Mice and Men and Armadillos

Next year's "FDA Voices" series will cover core topics FDA staff are prioritizing.

Voice of Regulators

The 1VQ papers advocate for the idea that certain post-approval changes should be streamlined and expedited.

Optimizing Quality

While the cost of certain medicines are alarmingly high, they can be considered a bargain measured against a lifetime of traditional costs.

What Does Cost Mean?

How can we fix the quality manufacturing issues that come with product shortages?

The Stick and Carrot of Quality Management

Systemic inefficiencies in the pharmaceutical industry undermine problem-solving efforts.

How Can We Come Up Short So Often?

AI could provide solutions to critical manufacturing inefficiencies.

Is AI a Panacea for Pharma’s Productivity Gap?

Spring has returned, and with it comes INTERPHEX.

Back to INTERPHEX

Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.

From the CEO